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Comorbidity profiles and inpatient outcomes
during hospitalization for heart failure: an analysis
of the U.S. Nationwide inpatient sample
Christopher S Lee1*, Christopher V Chien2, Julie T Bidwell3, Jill M Gelow2, Quin E Denfeld3, Ruth Masterson Creber4,
Harleah G Buck5 and James O Mudd2
Abstract
Background: Treatment of heart failure (HF) is particularly complex in the presence of comorbidities. We sought to
identify and associate comorbidity profiles with inpatient outcomes during HF hospitalizations.
Methods: Latent mixture modeling was used to identify common profiles of comorbidities during adult
hospitalizations for HF from the 2009 Nationwide Inpatient Sample (n = 192,327).
Results: Most discharges were characterized by “common” comorbidities. A “lifestyle” profile was characterized by a
high prevalence of uncomplicated diabetes, hypertension, chronic pulmonary disorders and obesity. A “renal”
profile had the highest prevalence of renal disease, complicated diabetes, and fluid and electrolyte imbalances. A
“neurovascular” profile represented the highest prevalence of cerebrovascular disease, paralysis, myocardial
infarction and peripheral vascular disease. Relative to the common profile, the lifestyle profile was associated with a
15% longer length of stay (LOS) and 12% greater cost, the renal profile was associated with a 30% higher risk of
death, 27% longer LOS and 24% greater cost, and the neurovascular profile was associated with a 45% higher risk
of death, 34% longer LOS and 37% greater cost (all p < 0.001).
Conclusions: Comorbidity profiles are helpful in identifying adults at higher risk of death, longer length of stay, and
accumulating greater costs during hospitalizations for HF.
Keywords: Heart failure, Comorbidity, Outcomes, Inpatient
Background
Management of the heterogeneous disorder of heart fail-
ure (HF) is particularly complex in the presence of comor-
bidities [1-3]. Nearly 60% of adults with HF have five or
more chronic comorbidities, a percentage that has in-
creased dramatically over the last twenty years [4]. Both
cardiovascular and non-cardiovascular comorbidities ob-
served among adults with HF contribute to condition de-
velopment, progression and prognosis [5-7]. Comorbidities
in HF also vary in etiological association [8], with some
conditions like myocardial infarction and peripheral vascu-
lar disease having risk factors in common, and others such
as cerebrovascular disease and dementia having a direct
causal link. Thus, although the influence of specific and/or
the number of comorbidities are important to our under-
standing of HF complexity, identifying naturally occurring
patterns among comorbidities may be more helpful in iden-
tifying subgroups of HF patients who are more vulnerable
to poor outcomes and who would benefit from tailored
management strategies [9,10].
Accordingly, the primary aim of this study was to iden-
tify and characterize distinct, common, and naturally-
occurring profiles among chronic comorbidities in adult
hospitalizations for HF. To quantify the clinical relevance
of these findings, we also sought to quantify associations
among observed comorbidity profiles and the inpatient out-
comes of all-cause death, length-of-stay (LOS) and costs.* Correspondence: leechri@ohsu.edu1Oregon Health & Science University School of Nursing and Knight
Cardiovascular Institute, 3455 SW US Veterans Hospital Road, Portland, OR
97239-2941, USA
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Methods
Data from the 2009 Agency for Healthcare Research and
Quality (AHRQ) Health Care Utilization Project Nation-
wide Inpatient Sample (NIS) were used for this study. The
NIS is the largest publicly available all-payer inpatient care
database in the U.S. The 2009 NIS contains all discharge
data from a sampling frame of 4,390 hospitals located in 44
States, representing an approximate 20% stratified sample
of U.S. community hospitals. This study was determined
to be exempt from ethical review by the Oregon Health &
Science University institutional review board because all
NIS data are de-identified and includes several other safe-
guards to protect the privacy of individual patients, physi-
cians and hospitals. This study conforms to the principles
of the Declaration of Helsinki. All hospital discharges were
examined for the diagnosis of HF by identifying AHRQ
clinical classification software [11] diagnosis category 108
(i.e. congestive HF, nonhypertensive (International Classi-
fication of Diseases, 9th Edition, Clinical Modifications
(ICD-9-CM) codes 398.91, 428.0 428.1 428.20 428.21
428.22 428.23 428.30 428.31 428.32 428.33 428.40 428.41
428.42 428.43 428.9)) [12] and additional ICD-9-CM
codes indicative of HF (402.01, 402.11, 402.91, 404.01,
404.03, 404.11, 404.13, 404.91, 404.93) [13,14] as the
principal diagnoses. In the NIS, the principal diagnosis
was the condition established after study to be chiefly
responsible for prompting the hospitalization. Hospital-
izations for HF were also verified as being urgent or
emergent (i.e. non-elective).
Assessment of comorbidities
In accordance with a common definition, comorbidities
were considered coexisting conditions to HF, the index
disorder under study [15]. AHRQ comorbidity software
[16] was used to generate binary variables that identify
29 comorbidities in discharge records using ICD-9-CM
codes. Seventeen Deyo-Charlson clinical comorbidities
[17] were also assessed using ICD-9-CM codes. There
was both overlap and additive value in comparing the
AHRQ and Deyo-Charlson comorbidities. Hence, a
complement of 25 comorbid illnesses from the AHRQ
software (acquired immunodeficiency syndrome, alcohol-
ism, deficiency anemia, rheumatoid arthritis/collagen vascu-
lar disease, chronic blood loss anemia, chronic pulmonary
disease, coagulopathy, depression, diabetes, uncompli-
cated, diabetes with chronic complications, drug abuse,
hypertension, hypothyroidism, lymphoma, fluid and elec-
trolyte disorders, metastatic cancer, other neurological dis-
orders, obesity, paralysis, peripheral vascular disorders,
psychoses, pulmonary circulation disorders, solid tumor
without metastasis, valvular disease and weight loss) and 7
comorbid illnesses from the Deyo-Charlson comorbidity
measures (acute myocardial infarction, cerebrovascular
disease, dementia, peptic ulcer disease, mild liver disease,
renal disease and moderate/severe liver disease). The
number of chronic comorbidities and Charlson Comor-
bidity Index categories of comorbid burden (low (1–2),
medium (3–4), high (5 or more)) [18] were also computed
for comparisons.
Inpatient outcomes
Death was defined in the NIS as in-hospital mortality, and
in this paper, is reported as all-cause. Length-of-stay was
calculated as the number of nights the patient remained in
the hospital for a particular discharge. Length-of-stay in
this analysis was all-cause. Total charges reported in the
2009 NIS were converted to costs using hospital-specific
cost-to-charge ratios based on actual accounting reports
from the Centers for Medicare and Medicaid Services.
Costs, in $U.S. 2009, reported in this paper were all-cause.
Statistical analysis
In accordance with the structure of the NIS database,
the primary unit of analysis was hospitalization. Means
and proportions with standard errors adjusted for dis-
charge weights were used to describe population esti-
mates derived from this sample. Latent class mixture
modeling was used to identify distinct and common co-
morbidity profiles among binary categorical variables in-
dicating the presence or absence of 32 complementary
comorbidities (performed with Mplus v.6, Los Angeles,
California). Latent class mixture model specification was
based on procedures explicated by Ram and colleagues
[19]. The Lo-Mendell-Rubin adjusted likelihood ratio test
(LMRT) [20], convergence (entropy near 1.0), sufficient
proportions of the sample in each profile, and posterior
probabilities (average probability of belonging in “most
likely” profile near 1.0) were used to compare alternative
models (e.g. k vs. k-1 profiles) [21,22]; discharge weights
were incorporated into all latent class models. Observed
profiles were labeled according to dominant and differenti-
ating comorbidities. Differences in comorbidities among
observed profiles were quantified using χ2 tests. Multi-
nomial logistic regression models were generated to calcu-
late marginal probabilities (range −1 to 1, sum to zero) [23]
of belonging to each profile based on single comorbid
conditions.
Generalized linear modeling was used to quantify associ-
ations among observed comorbidity profiles and inpatient
death (relative risk (RR)) length-of-stay (incident rate ratio
(IRR) based on the negative binomial distribution cor-
rected for over-dispersion) and inpatient costs (gamma
distribution for relative differences, and Duan’s smearing
retransformation of log-transformed cost [24] to estimate
absolute differences in raw 2009 U.S. dollars) (performed
with Stata v.11MP, College Station, Texas). Associations
between the number of comorbidities and Charlson cat-
egories of comorbid burden and inpatient outcomes also
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were generated for context and comparison. Discharge
weights were applied in all generalized linear models, and
all estimates were adjusted for age, gender, race, median
income of the patient’s zip code, primary expected health-
care payer, and weekend vs. weekday admissions, as well
as hospital bed size (small, medium, or large) control (gov-
ernment or private, government/nonfederal (public), pri-
vate/non-profit, private/investor owned, private), location
(rural, urban), region (Northeast, Midwest, South, West)
and teaching status (non-teaching, teaching).
Results
Characteristics of the population
The sample consisted of 192,327 hospitalizations (popula-
tion estimate = 976,664) with HF listed as the principal
diagnosis (Table 1). Approximately 51% of discharges were
for women, and the average age was almost 73 years.
Death occurred during just over 3% of hospitalizations,
the average length-of-stay was 5.2 days (median = 4 days),
and the average inpatient cost was $11,313 (Table 2). In
total, there were 12,966 inpatient deaths, 2.2 million in-
patient days, and $4.6 billion in inpatients costs translating
to population estimates of 30,798 deaths, 5.1 million in-
patient days, and a total of $10.3 billion in inpatient costs.
Number of comorbid illnesses, Charlson categories and
inpatient outcomes
The most prevalent comorbidities in this sample were
hypertension, renal disease, chronic pulmonary disease,
uncomplicated diabetes mellitus, and deficiency anemia
(Figure 1). The average number of comorbid illnesses
was 7.5, and the vast majority of discharges (82.4%) were
for patients with a high Charlson comorbidity category
(Table 2). There was a relatively small, but positive influence
of the number of comorbidities on the risk of inpatient
death (RR = 1.03, 95% confidence interval (CI) =1.02 -1.04),
length-of-stay (IRR = 1.05, 95% CI =1.04-1.05), and inpatient
cost (relative increase = 5.4%, 95% CI =5.1%-5.6%) (all p <
0.0001). Only 0.3% of discharges were for adults with a low
Charlson comorbidity category – a subgroup too small for
effective comparisons. Discharges for adults with a high vs.
a medium Charlson comorbidity category, however, were
associated with a greater risk of inpatient death (RR = 1.16
(95% CI = 1.08-1.25), longer length of stay (IRR = 1.15
(95% CI = 1.13-1.17), and greater inpatient cost (relative
increase = 12.5%, 95% CI =10.3%-14.7%) (all p < 0.0001).
Identifying profiles of comorbidity
Among the 32 conditions considered, four distinct comor-
bidity profiles were identified (model entropy = 0.71;
LMRT= 16,296; p < 1×10−7). The largest profile (n = 89,518
(46.7%), Figure 2-A), which was labeled as “common,” in-
cluded HF discharges with relatively few, but common co-
morbidities. There were 2 fewer comorbidities on average
in the common profile than the other profiles. The com-
mon profile also had the lowest prevalence of cerebrovascu-
lar disease (0.8%), myocardial infarction (13.9%), peripheral
vascular disorders (5.2%), depression (7.5%), renal disease
(0.5%), fluid and electrolyte disorders (20.8%), hypertension
(55.8%), and obesity (9.3%) compared with the other pro-
files. The prevalence of uncomplicated diabetes in the com-
mon profile was 27.4% and there were no cases of diabetes
with chronic complications. The common profile, named
in part because of the size of the profile and the relatively
limited comorbid burden, served as a reference to which
the other profiles could be compared.
A “lifestyle” profile (n = 37,797 (19.6%), Figure 2-B) was
characterized by a greater percentage of HF discharges with
uncomplicated diabetes, hypertension, chronic pulmon-
ary disorders and obesity than any other profile (all p <
1×10−7). A “renal” profile (n = 57,228 (29.6%), Figure 2-C)
had a greater percentage of HF discharges with renal dis-
ease, diabetes with complications and fluid and electrolyte
imbalances than any other profile (all p < 1x10−7). Finally,
a “neurovascular” profile (n = 7,784 (4.1%), Figure 2-D)
had a greater percentage of HF hospitalizations with cere-
brovascular disease, paralysis, myocardial infarction, per-
ipheral vascular disease, neurological disorders and
depression than any other profile (all p < 1×10−7).
Key profile-differentiating comorbidities are presented in
Table 3. In the presence of paralysis, the probability of be-
longing to the neurovascular comorbidity profile is 91.1%
and the probability of belonging to the other profiles is dra-
matically reduced. Similarly, the presence of cerebrovascu-
lar disease is associated with a high probability (76.5%) of
belonging to the neurovascular profile and reduced prob-
ability of belonging to the other comorbidity profiles. The
presence of diabetes with complications (73.8%) and renal
disease (53.3%) increases the probability of belonging to the
renal profile, and the presence of uncomplicated diabetes
(57.3%) and obesity (22.7%) increase the probability of hav-
ing the lifestyle profile of comorbidities.
Profiles of comorbidity and inpatient outcomes
Associations among observed comorbidity profiles and in-
patient outcomes are presented in Table 4. Relative to the
common comorbidity profile, inpatient death was 30.2%
more likely for HF discharges fitting renal profile and
44.5% more likely for HF discharges fitting the neurovas-
cular profile (both p < 1×10−7). Relative to the common
comorbidity profile, discharges within the lifestyle profile
were associated with a 14.9% longer length of stay, dis-
charges within the renal profile were associated with a
26.9% longer length of stay, and HF discharges fitting the
neurovascular profile were associated with a 33.6% longer
length of stay (all p < 1×10−7). In raw days of length-of-
stay, hospitalizations for patients fitting the lifestyle co-
morbidity profile were 0.68 days longer, hospitalizations
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for patients fitting the renal profile were 1.26 days longer,
and hospitalizations for patients fitting the neurovascular
profile were 1.57 days longer on average than HF dis-
charges fitting the common profile (all p < 1×10−7). Rela-
tive to the common comorbidity profile, discharges within
the lifestyle profile were associated with 11.9% greater in-
patient costs, those fitting the renal profile were associ-
ated with 23.5% greater inpatient costs, and those
within the neurovascular profile were associated with
36.7% greater inpatient costs (all p < 1×10−7). In raw
2009 US dollars, hospitalizations for patients fitting the
lifestyle profile cost $1,422.36 more, hospitalizations for
patients fitting the renal profile cost $2,199.26 more,
and hospitalizations for patients fitting the neurovascu-
lar profile cost $2,809.39 more on average compared
with HF discharges fitting the common profile.
Discussion
Management of HF is complicated by prevalent cardiovas-
cular and non-cardiovascular comorbidities [25]. In this
nationally-representative inpatient sample of 192,327 adult
hospitalizations with a principal diagnosis of HF, there was
an average of 7.5 comorbidities and the vast majority of
hospitalizations (82.4%) were categorized as having a high
Charlson comorbid burden. The main finding of this study
is the identification of four distinct and naturally occurring
Table 1 Characteristics of the sample (n = 192,327*)
Discharge and hospital
characteristics
Estimate
(mean or proportion)
95% CI
Age (in years) 72.88 (72.82-72.95)
Gender (% female) 50.77% (50.55%-51.00%)
Race/Ethnicity†
White 68.02% (67.79%-68.24%)
Black 18.98% (18.79%-19.17%)
Hispanic 7.73% (7.61%-7.86%)
Asian or Pacific Islander 1.79% (1.72%-1.85%)
Native American 0.54% (0.51%-0.58%)
Other 0.30% (0.29%-0.30%)
Median zip code income
national quartile
First 31.60% (31.39%-31.81%)
Second 27.00% (26.80%-27.21%)
Third 22.63% (22.44%-22.82%)
Fourth 18.77% (18.59%-18.95%)
Primary healthcare payer
Medicare 74.31% (74.11%-74.51%)
Medicaid 7.99% (7.87%-8.11%)
Private insurance 12.24% (12.09%-12.39%)
Self-pay 3.54% (3.46%-3.63%)
No charge 0.32% (0.30%-0.36%)
Other 1.59% (1.54%-1.65%)
Admission on a weekend 23.42% (23.23%-23.60%)
Hospital bed size
Small 13.28% (13.12%-13.43%)
Medium 23.88% (23.68%-24.07%)
Large 62.85% (62.63%-63.07%)
Control
Government or private 59.53% (59.31%-59.75%)
Government, nonfederal 7.18% (7.07%-7.30%)
Private, non-profit 18.37% (18.20%-18.55%)
Private, investor owned 10.72% (10.58%-10.86%)
Private 4.19% (4.10%-4.28%)
Location
Rural 14.92% (14.76%-15.08%)
Urban 85.08% (84.92%-85.23%)
Region
Northeast 22.35% (22.16%-22.54%)
Midwest 23.40% (23.21%-23.59%)
South 39.37% (39.15%-39.59%)
West 14.87% (14.72%-15.03%)
Table 1 Characteristics of the sample (n = 192,327*)
(Continued)
Teaching status
Non-teaching 58.78% (58.56%-59.00%)
Teaching 41.22% (41.00%-41.44%)
*Estimates generated using discharge weights (population estimate n = 976,664).
†data missing for 14.3% of discharges. CI, confidence interval.
Table 2 Comorbidities and outcome characteristics
(n = 192,327*)
Comorbidities
and outcomes
Estimate
(mean or proportion)
95% CI
Number of
comorbidities
7.54 (7.53-7.55)
Charlson comorbidity
category
Low (1–2) 0.29% (0.26%-0.31%)
Medium (3–4) 17.29% (17.12%-17.46%)
High (5+) 82.42% (82.25%-82.60%)
Inpatient death 3.15% (3.08%-3.23%)
Inpatient length
of stay (days)
5.22 (5.20-5.25)
Inpatient cost
(2009 $US)
$11,313.28 ($11,233.77-$11,329.80)
*Estimates generated using discharge weights (population estimate n = 976,664).
Abbreviations: CI, confidence interval.
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comorbidity profiles that were associated with significant
differences in the all-cause inpatient outcomes of death,
length-of-stay and cost. Relative to the 46.7% of hospitali-
zations with a “common” comorbidity profile, the 19.6% of
HF hospitalizations fitting a “lifestyle” profile had longer
length-of-stay and greater costs, and the 29.6% of HF hos-
pitalizations within a “renal” comorbidity profile and the
4.1% of HF hospitalizations with a “neurovascular” comor-
bidity profile were associated with higher risk of inpatient
death, longer length-of-stay and greater costs.
Similar to the findings of other studies, we observed a
direct relationship between the number of comorbidities
[26-28] as well as categories of Charlson comorbid burden
[29] and clinical outcomes among adults with HF. Specif-
ically, we observed an adjusted 3%-5% increase in the risk
of death, extension in length-of-stay and accrual of in-
patient costs for additional comorbidities. The number of
comorbidities and the proportion of discharges associated
with 5 or more comorbidities in this sample are greater
than prior reports in HF [4,28], which can be explained, at
least in part, by our inclusion of 32 comorbidities that
were of both cardiovascular and non-cardiovascular ori-
gin. An extreme minority of hospitalizations in this sample
involved patients with a low comorbid burden; thus, we
compared hospitalizations fitting a moderate and high
Charlson comorbid risk. High Charlson comorbid burden
was associated with 12%-16% increase in the risk of death,
extension in length-of-stay and accrual of inpatient costs
compared with hospitalizations for adults with a moderate
comorbid burden. In sum, our findings provide further
evidence in support of both the number of comorbidities
and categorization of comorbid burden as having a signifi-
cant influence on inpatient outcomes in HF.
There is elegance in the simplicity of counting comor-
bidities, considering thresholds that represent complex
comorbidity (i.e. 5 or more), and weighing counts of co-
morbidities based on established associations with 1-year
mortality (i.e. Charlson). A major limitation to these ap-
proaches to comorbidities in HF, however, is the inability
to consider how some comorbidities are naturally inde-
pendent, others have common risk factors and/or patho-
genic pathways, and others still have direct causation [8].
Moreover, single comorbidity inventories often omit key
conditions that are highly-prevalent in HF (e.g. the
Charlson excludes hypertension, and the AHRQ comor-
bidities do not include myocardial infarction), and inef-
fectively capture condition severity (e.g. the Charlson does
not differentiate diabetes with and without complications,
and the AHRQ comorbidities do not differentiate mild
from moderate to severe liver disease). Thus, our finding
of four distinct, naturally-occurring profiles among co-
morbidities in adult HF hospitalizations builds upon prior
research that has involved single comorbidity inventories
or considered all comorbidities as being etiologically and
statistically independent.
The largest comorbidity profile we observed involved
the fewest and common comorbidities. In fact, the only
differentiating factors to identity patients fitting this pro-
file were prevalent HF comorbidities (e.g. hypertension,
chronic pulmonary disease, and uncomplicated diabetes)
and the absence of renal disease, which had an overall
prevalence of 39% but only affected 0.5% of discharges in
this profile. Based on this sample, there is an estimated
455,851 hospitalizations in the U.S. for HF patients fitting
this comorbidity profile annually, and they experience the
most favorable inpatient outcomes. The next hazardous
profile we observed was differentiated by comorbidities
that are linked to lifestyle, including 100% prevalence of
uncomplicated diabetes, 84% prevalence of hypertension,
40% prevalence of chronic pulmonary disease, and 27%
Figure 1 Prevalence of comorbidities in adult hospitalizations with a principal diagnosis of heart failure. Prevalence estimates were
generated using discharge weights (n = 192,327; population estimate n = 976,664). Only conditions with a prevalence of 5% or greater are
displayed for economy of presentation.
Lee et al. BMC Cardiovascular Disorders 2014, 14:73 Page 5 of 9
http://www.biomedcentral.com/1471-2261/14/73
Table 3 Key differentiating comorbidities: marginal probabilities (n = 192,327*)
Comorbidity Common n = 89,518†
(46.7%)
Lifestyle n = 37,797†
(19.6%)
Renal n = 57,228†
(29.6%)
Neurovascular
n = 7,784† (4.1%)
Paralysis −0.422 −0.187 −0.302 0.911
Cerebrovascular disease −0.417 −0.129 −0.220 0.765
Diabetes with complications −0.515 −0.217 0.738 −0.006
Renal disease −0.755 0.224 0.533 −0.002
Diabetes, uncomplicated −0.142 0.573 −0.428 −0.003
Obesity −0.175 0.227 −0.028 −0.024
All marginal probabilities were statistically significant (all p < 0.0001). Marginal effects in probability scale sum to zero for each comorbidity, with values closest to ±1.0
indicating the strongest differentiation.
*Estimates generated using discharge weights (population estimate n = 976,664).
†Population estimates for totals of discharges fitting the common, lifestyle, renal and neurovascular comorbid illness profiles were 455851, 191595, 289613, and
39604, respectively.
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Figure 2 Four observed comorbidity profiles in adult hospitalizations with a principal diagnosis of heart failure. Radar graphs present
within-profile prevalence of differentiating comorbidities from 0% (center of graph) to 100% (outside of graph). The common profile (A) had the
lowest prevalence of cerebrovascular disease, myocardial infarction, peripheral vascular disorders, depression, renal disease, fluid and electrolyte
disorders, hypertension, and obesity compared with the other profiles. Key attributes of the lifestyle profile (B) were high rates of uncomplicated
diabetes, hypertension, chronic pulmonary disorders and obesity. Key attributes of the renal profile (C) were high rates of renal disease, diabetes
with complications and fluid and electrolyte imbalances. Key attributes of the neurovascular profile (D) were high rates of cerebrovascular disease,
paralysis, myocardial infarction, peripheral vascular disease, neurological disorders and depression. Prevalence estimates were generated using discharge
weights (n = 192,327; population estimate n = 976,664). All differences by comorbidity profile were statistically significant (all p < 0.0001).
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prevalence of obesity. The triad of diabetes, hypertension
and obesity is well-recognized as integral characteristics of
metabolic syndrome [30], and majority of chronic pul-
monary disease is thought to be attributable to cigarette
smoking [31]. There is an estimated 191,595 annual hospi-
talizations for HF patients fitting this lifestyle comorbidity
profile that is associated with longer length-of-stay and
greater inpatient cost. Fitting the lifestyle profile on dis-
charges for HF should serve as a red flag for greater health-
care utilization, and interventions to reduce the risk of poor
inpatient outcomes for this profile should be tailored to im-
proving lifestyle in general in addition to treating specific
comorbidities. Since hypertension and diabetes mellitus
were prominent features of both the common and lifestyle
comorbidity profiles, dietary modifications and aerobic exer-
cise are two specific lifestyle recommendations that may be
helpful in the reduction of cardiovascular risk in these two
groups [32]. It is also known that hypertension and obesity
are more prevalent among HF patients with preserved versus
reduced ejection fraction [33]; thus, interventions to reduce
the risk of poor clinical outcomes may be further tailored by
HF type within the observed comorbidity profiles.
The next hazardous profile we observed was centered on
a high prevalence of renal disease (82%) and diabetes with
complications (31%). The combination of renal disease and
diabetes has been shown by others to be associated greater
risk of death and hospitalization in HF [34]. Over 3/4 of HF
discharges within this renal profile also had hypertension
and slightly more than 1/3 had fluid and electrolyte disor-
ders. Diabetes and hypertension are widely recognized as
the leading causes of renal disease [35], and cardiorenal
syndrome [36] is a challenging condition to manage par-
ticularly during acute hospitalization for HF [37]. Given the
nature of these data, it is not possible to understand the
temporal and/or causal nature of relationships among the
key differentiating comorbidities in the renal or other pro-
files. But, HF hospitalizations for patients fitting this profile
were associated with a 30% increase in the risk of inpatient
death and 27% and 24% increases in length-of-stay and in-
patient costs, respectively and there is an estimated 289,613
annual HF discharges in the U.S. for patients fitting this co-
morbidity profile.
The most hazardous comorbidity profile identified was
differentiated from the others by extremely high rates of
cerebrovascular disease, and the highest prevalence of par-
alysis, myocardial infarction, peripheral vascular disorders,
neurologic disorders and depression. Peripheral vascular
disease is often paired with comorbid cerebrovascular dis-
ease [38], and is a determinant of worse outcomes in pa-
tients with myocardial infarction [39]. There also is a link
between both cerebrovascular disease [40] and myocardial
infarction [41] and depression. Thus, end-organ damage of
global vascular disease appeared to be central to this profile.
Based on this sample there are more than 39,000 HF hospi-
talizations for patients fitting this neurovascular comorbid-
ity profile in the U.S. annually; there was a 45% increase in
the risk of inpatient death, 34% increase in length-of-stay
and 37% increase in inpatient cost associated with dis-
charges for HF patients fitting this profile. Patients fitting
the renal or neurovascular profiles upon admission for HF
should be assumed to require greater healthcare utilization
and should be enrolled in disease management and care
transition programs to mitigate the overall impact on global
healthcare resources and improve patients’ quality-of-life.
There are several existing schemes for classifying the risk
of poor inpatient outcomes in HF. For example, Fonarow
and colleagues determined that blood urea nitrogen, admis-
sion systolic blood pressure, and serum creatinine were pre-
dictive of inpatient mortality among adults admitted for
decompensated HF [42]. Coronary artery disease, renal in-
sufficiency and diabetes were more prevalent in the high-
versus the low-risk groups in that study. As an additional
example, Peterson and group determined that age, systolic
blood pressure, blood urea nitrogen, heart rate, serum so-
dium, coexisting chronic obstructive pulmonary disease,
and race were predictive of inpatient mortality among adults
admitted for decompensated HF [43]. Thus, the incorpor-
ation of coexisting comorbidities into inpatient prognostic
models is not new. But, what our findings add to extant
knowledge about the influence of comorbidities on in-
patient outcomes is a new approach the naturally-occurring
clusters of prevalent and coexisting that complicate HF ad-
missions and are associated with significant differences in
inpatient outcomes.
Table 4 Adjusted differences in inpatient outcomes by comorbidity profile (n = 192,327*)
Inpatient death Length-of-stay Inpatient cost
Comorbidity profile RR (95% CI) p-value IRR (95% CI) p-value Relative cost (95% CI) p-value
Lifestyle† 1.023 (0.945-1.108) 0.573 1.149 (1.135-1.163) <0.001 111.9% (110.0%-113.9%) <0.001
Renal† 1.302 (1.223-1.387) <0.001 1.269 (1.254-1.284) <0.001 123.5% (121.5%-125.4%) <0.001
Neurovascular† 1.445 (1.280-1.631) <0.001 1.336 (1.291-1.381) <0.001 136.7% (131.3%-142.3%) <0.001
Note: All estimates are adjusted for age, gender, race, median income of the patient’s zip code, primary healthcare payer, and weekend vs. weekday admissions, as
well as hospital bed size (small, medium, or large) control (government or private, government/nonfederal (public), private/non-profit, private/investor owned,
private), location (rural, urban), region (Northeast, Midwest, South, West) and teaching status (non-teaching, teaching).
*Estimates generated using discharge weights (population estimate n = 976,664).
†Relative to the “common” comorbidity profile.
Abbreviations: CI, confidence interval calculated from weighted standard errors; IRR, incident rate ratio; RR, relative risk.
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Strengths and limitations
The present study has strengths and limitations. Using
the NIS as a nationally-representative sample of pa-
tients admitted for the principal diagnosis of HF and
applying sampling weights allows us to generalize esti-
mates for comorbidity prevalence, composition of co-
morbidity profiles and inpatient outcomes that are
generalizable to a much larger population than the
sample studied. Tradeoffs for this strength are the limi-
tations of using hospitalization (and not patient) as the
unit of analysis, and that national representativeness
does not translate to generalizability to all persons with
HF. There are also challenges to using ICD-9-CM
codes for the identification of HF and comorbidities
alike. The ICD-9-CM codes chosen for this study, how-
ever, are highly predictive of HF when compared with
clinical criteria [12], and are established codes for per-
formance measures in HF [13]. Like most research in-
volving administrative databases, there may have been
under-reporting of chronic comorbidities in the NIS
[44]. It is also likely that the comorbidity profiles we
identified are dynamic rather than fixed; thus, these
profiles are likely to evolve over time along with the
progression of both HF and concomitant comorbidi-
ties. We are also unable to distinguish casual relation-
ships among comorbidities, those simple having risk
factors in common and the potential pathological links
to HF (e.g. complication of, predisposing factor for, or
unrelated) in this single evaluation of administrative
data; hence, that was not our goal.
We also did not differentiate between HF with pre-
served or unpreserved ejection fraction. There are im-
portant socio-demographic (e.g. older age and female
gender), etiological (e.g. greater prevalence of hyperten-
sion and atrial fibrillation, and less frequent coronary
artery disease) [45], and non-cardiovascular comorbid-
ity differences (e.g. high prevalence of chronic lung,
liver and gastric disorders) comparing HF patients with
preserved versus reduced ejection [46]. Hence, it will be
important to differentiate comorbidity profiles by groups
of HF patients with preserved and reduced ejection frac-
tion in future research. Because of the administrative na-
ture of this data source, we were unable to incorporate
granular clinical data (e.g. ejection fraction, which ventri-
cles are involved, blood pressure, glomerular filtration rate,
and functional performance measures). Hence, future re-
search is warranted to examine the influence of comorbid-
ity profiles along with clinical data including, but not
limited to, a) the assessment of HF with preserved ver-
sus reduced ejection fraction, b) the natural history of
comorbidities over time and how they relate to the evo-
lution of HF, c) different manifestations of HF (e.g. left,
right, or bi-ventricular dysfunction), and d) other prog-
nostic clinical data.
Conclusion
Among a large sample of adult hospitalizations for HF,
we observed four distinct comorbidity profiles that were
associated with large and significant differences in the
risk of inpatient death, length-of-stay and inpatient cost.
Naturally-occurring patterns of cardiovascular and non-
cardiovascular comorbidities, not simply the number of
comorbidities, should be the focus of future research
and the target of future interventions aimed at reducing
the risk of inpatient death and healthcare utilization.
Abbreviations:
AHRQ: Agency for Healthcare Research and Quality; CI: Confidence interval;
HF: Heart failure; ICD-9-CM: International Classification of Diseases, 9th Edition,
Clinical Modifications; IRR: Incident rate ratio; LMRT: Lo-Mendell-Rubin
adjusted likelihood ratio test; LOS: Length of stay; NIS: Nationwide inpatient
sample; RR: Relative risk.
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